This study is in progress, not accepting new patients
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
Description
Summary
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- SecuraBio
- ID
- NCT01882803
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- At least 129 people participating
- Last Updated